Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

Phamacology monitoring and drug-drug interactions in older patients with cancer

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Submit
Thanks for rating
There has been a problem, please refresh and try again.
Published: 29.11.19
Views: 436
Rating:

Dr Ginah Nightingale - Thomas Jefferson University, Philadelphia, USA

Dr Ginah Nightingale speaks to ecancer at the SIOG 2019 meeting in Geneva about the prevalence and monitoring of drug-drug interactions (DDIs) in elderly cancer patients.

She mentions the high prevalence of DDIs, which may be attributed to polypharmacy, as these patients are prescribed numerous medications due to their increased co-morbidities.

Dr Nightingale describes a study which focuses on the prevalence of DDIs between proton-pump inhibitors which inhibit the absorption of tyrosine-kinase inhibitors, which are commonly prescribed to treat a variety of malignancies in older adults - leading to an increased risk of mortality.

She concludes by discussing what steps can be taken to reduce the prevalence of DDIs and the consequences of them in the clinic.

This service has been kindly supported by unrestricted grants from Janssen Oncology and Sanofi Genzyme.

Related videos

follow us

Donate to ecancer


Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation